An industry-funded cluster-randomized trial found that clinician alerts were associated with an over 40% increase in prescription of four recommended drug classes in patients with heart failure with reduced ejection fraction.
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
Researchers performed a secondary analysis of the PROMISE trial to determine the relationship between coronary artery disease (CAD) symptoms at presentation and resulting processes of care, test results, and clinical outcomes.
This year's meeting features keynote speaker Quinn Capers, MD, on Thursday, April 28, and plenary speakers Mukta Panda, MD, MACP, and Tammy L. Lin, MD, MPH, FACP, on Saturday, April 30.
Physicians looking for a job may submit a job seeker's profile and/or upload their CV to reach participating employers.